Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, Roche Files IND for Genmab Antibody13 Dec 2005
Genmab, articles of association dated December 01 200513 Dec 2005
Genmab, Announces Responses with HuMax-CD4™ in Non-Cutaneous T-Cell Lymphoma12 Dec 2005
Genmab, HuMax-CD38 Effective in Preclinical Studies12 Dec 2005
Genmab, HuMax-CD20 Induces Rapid Responses in Relapsed CLL Patients12 Dec 2005
Genmab, Grant of Warrants in Genmab A/S2 Dec 2005
Genmab, insiders' tradings2 Dec 2005
Genmab, Announces Data on All Evaluable Patients in HuMax®-CD20 NHL Phase I/II Study
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
1 Dec 2005
Genmab, Capital Increase in Genmab as a Result of Employee Warrant Exercise1 Dec 2005
Genmab, articles of association8 Nov 2005
Genmab, quarterly report Q3 20058 Nov 2005
Genmab, Announces Results for the First Nine Months of 20058 Nov 2005
  • Previous
  • 1
  • More pages
  • 130
  • 131
  • 132
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863